EMAIL THIS PAGE TO A FRIEND

Experimental neurology

Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice.


PMID 25797577

Abstract

Intracerebral hemorrhagic stroke (ICH) causes high mortality and morbidity with very limited treatment options. Cell-based therapy has emerged as a novel approach to replace damaged brain tissues and promote regenerative processes. In this study we tested the hypothesis that intranasally delivered hypoxia-preconditioned BMSCs could reach the brain, promote tissue repair and improve functional recovery after ICH. Hemorrhagic stroke was induced in adult C57/B6 mice by injection of collagenase IV into the striatum. Animals were randomly divided into three groups: sham group, intranasal BMSC treatment group, and vehicle treatment group. BMSCs were pre-treated with hypoxic preconditioning (HP) and pre-labeled with Hoechst before transplantation. Behavior tests, including the mNSS score, rotarod test, adhesive removal test, and locomotor function evaluation were performed at varying days, up to 21days, after ICH to evaluate the therapeutic effects of BMSC transplantation. Western blots and immunohistochemistry were performed to analyze the neurotrophic effects. Intranasally delivered HP-BMSCs were identified in peri-injury regions. NeuN+/BrdU+ co-labeled cells were markedly increased around the hematoma region, and growth factors, including BDNF, GDNF, and VEGF were significantly upregulated in the ICH brain after BMSC treatment. The BMSC treatment group showed significant improvement in behavioral performance compared with the vehicle group. Our data also showed that intranasally delivered HP-BMSCs migrated to peri-injury regions and provided growth factors to increase neurogenesis after ICH. We conclude that intranasal administration of BMSC is an effective treatment for ICH, and that it enhanced neuroregenerative effects and promoted neurological functional recovery after ICH. Overall, the investigation supports the potential therapeutic strategy for BMSC transplantation therapy against hemorrhagic stroke.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV41333
Anti-DCX (AB1) antibody produced in rabbit, affinity isolated antibody
AV41332
Anti-DCX (AB2) antibody produced in rabbit, affinity isolated antibody
SAB2502091
Anti-Dcx antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501666
Anti-DCX antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405701
Anti-DCX antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
D9818
Anti-Doublecortin (C-terminal) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
D9943
Anti-Doublecortin (N-terminal) antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
D9693
Anti-Doublecortin antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB4300697
Anti-Doublecortin antibody produced in rabbit, affinity isolated antibody
SAB4500628
Anti-Doublecortin antibody produced in rabbit, affinity isolated antibody
SAB4500629
Anti-Doublecortin, C-Terminal antibody produced in rabbit, affinity isolated antibody
WH0001641M1
Monoclonal Anti-DCX antibody produced in mouse, clone 1G12, purified immunoglobulin, buffered aqueous solution
SAB1403727 Monoclonal Anti-DCX antibody produced in mouse, clone 3B7, purified immunoglobulin, buffered aqueous solution